Just caught wind of some solid news from Eli Lilly on the pharma side - their Retevmo (selpercatinib) just hit the primary endpoint in the Phase 3 LIBRETTO-432 trial for early-stage RET-positive lung cancer. This is actually pretty significant for the space.

The trial showed statistically significant improvement in event-free survival compared to placebo in patients with early-stage (Stage II-IIIA) RET fusion-positive non-small cell lung cancer. What's interesting here is that LIBRETTO-432 is the first and only randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy in this patient population - so Lilly basically set the bar for this indication.

Retevmo itself is an oral RET kinase inhibitor with CNS penetration, dosed at 120mg or 160mg twice daily depending on patient weight. The safety profile in LIBRETTO held up well and was consistent with what they've seen in earlier development work.

One thing worth noting - overall survival data trended favorably for selpercatinib, but they noted it's still immature with limited events so far. That's pretty typical for adjuvant trials though.

Lilly's planning to present the full data at a medical conference soon and submit to peer-reviewed journals. Their oncology head Jacob Van Naarden made the point that this could help push genomic testing adoption for early-stage lung cancer patients, similar to how EGFR and ALK testing became standard. The LIBRETTO results could accelerate that shift toward precision medicine in early disease.

Interesting to see how this plays out in the competitive landscape for early-stage lung cancer treatment.